DOES THE CONTINUOUS USE OF BRONCHODILATORS MASK THE PROGRESSION OF ASTHMA OR CHRONIC-BRONCHITIS

被引:17
作者
VANSCHAYCK, CP
FOLGERING, H
DENOTTER, JJ
TIRIMANNA, P
VANWEEL, C
机构
[1] Nijmegen University, Nijmegen, 6500 HB
关键词
D O I
10.1093/fampra/9.4.397
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Recently, we published data of a 2 year randomized controlled study in which the effects of continuous versus symptomatic bronchodilator treatment in patients with moderate asthma or chronic bronchitis were investigated. The results showed that FEV1 decline in the continuously treated group was significantly larger than in the symptomatically treated group (72 versus 20 ml/year, P < 0.05). We reanalysed these data in order to investigate the hypothesis that the continuous use of bronchodilators may mask a rapid decline in lung function. Lung function decline was assessed by regression analysis of seven FEV1 measurements. Respiratory symptoms were assessed by means of the MRC questionnaire every 12 months, and they were also recorded by the patients in a weekly report. Of the participating patients 144 completed the study. Increased lung function decline in the continuously treated group was not reflected in a significant deterioration of the symptoms. Moreover, the decline in FEV1 showed no correlation at all with changes in respiratory symptoms in continuously treated patients (r = -0.03, P = 0.80), whereas in the symptomatically treated group, there was a better relation (r = -0.32, P = 0.003) to changes in respiratory symptoms. These results show that continuous bronchodilatation may indeed mask the worsening of the disease. This lack of awareness of deterioration of the disease is probably caused by the continuous symptom relief of bronchodilators. It may be misleading to both patients and physicians.
引用
收藏
页码:397 / 404
页数:8
相关论文
共 31 条
[1]  
Van Schayck C.P., Van Weel C., Folgering H., Verbeek A., Van Herwaarden C.L.A., Treatment of patients with airflow obstruction by general practitioners and chest physicians, Scand J Prim Health Care, 7, pp. 137-142, (1989)
[2]  
Sears M.R., Rea H.H., Fenwick J., Gillies A., 75 Deaths in asthmatics prescribed home nebulizers, Br Med J, 294, pp. 477-480, (1987)
[3]  
Crane J., Flatt A., Jackson R., Prescried fenoterol and death from asthma in New Zealand, 1981-83: Case-control study, Lancet, pp. 917-922, (1989)
[4]  
Sears M.R., Taylor D.R., Print C.G., Et al., Regular inhaled beta-agonist treatment in bronchial asthma, Lancet, 336, pp. 1391-1396, (1990)
[5]  
Van Schayck C.P., Graafsma S.J., Visch M.B., Dompeling E., Van Weel C., Van Herwaarden C.L.A., Increased bronchial hyperresponsiveness after inhaling salbutamol during one year is not caused by subsensitization to salbutamol, J Allergy Clin Immunol, 86, pp. 793-800, (1990)
[6]  
Van Schayck C.P., Dompeling E., Van Herwaarden C., Et al., Bronchodilator treatment in moderate asthma or chronic bronchitis: Continuous or on demand? A randomised controlled study, Br Med J, 303, pp. 1426-1431, (1991)
[7]  
Spitzer W.O., Suissa S., Ernst Pet al. The use of/1-agonists and the risk of death and near death from asthma, N Engl J Med, 326, pp. 501-506, (1992)
[8]  
Barnes P.J., Effect of corticosteroids on airway hyperresponsiveness, Am Rev Respirdis, 141, pp. 70-76, (1990)
[9]  
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma, Am Rev RespirDis, 136, pp. 225-243, (1987)
[10]  
Van Schayck C.P., Folgering H., Harbers H., Maas C.L., Van Weel C., Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis, Thorax, 46, pp. 355-359, (1991)